SEC Company Response from ReShape Lifesciences Inc. (RSLS) (CIK 0001427570) (HIND) — Oct 3, 2016
ReShape Lifesciences Inc. (RSLS) (CIK 0001427570)
Date: Oct. 3, 2016 · CIK: 0001427570 · Accession: 0001193125-16-729062
AI Filing Summary & Sentiment
File numbers found in text: 333-213551
Letter
OBALON THERAPEUTICS, INC.
5421 Avenida Encinas, Suite F
Carlsbad, California 92008
October 3, 2016
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Attention:
Amanda Ravitz
Geoff Kruczek
Caleb French
Kate Tillan
Tara Harkins
Re:
Obalon Therapeutics, Inc. Registration Statement on Form S-1 (File No. 333-213551) filed September 9, 2016, as amended
Requested Date: October 5, 2016
Requested Time: 4:00 PM Eastern Time
Ladies and Gentlemen:
Obalon Therapeutics, Inc. (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to declare the above-captioned Registration Statement on Form S-1 effective at the “Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable, or at such later time as the Registrant may orally request via telephone call to the staff of the Commission (the “Staff”).
The Registrant hereby authorizes Robert Freedman or Amanda Rose, both of whom are attorneys with the Registrant’s outside legal counsel, Fenwick & West LLP, to orally modify or withdraw this request for acceleration.
The Registrant hereby acknowledges that:
•
should the Commission or the Staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
•
the action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
•
the Registrant may not assert the Staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
The Registrant requests that it be notified of such effectiveness by a telephone call to Mr. Freedman at (650) 335-7292 or in his absence, Ms. Rose at (206) 389-4553.
Sincerely,
OBALON THERAPEUTICS, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP OBALON THERAPEUTICS, INC. 5421 Avenida Encinas, Suite F Carlsbad, California 92008 October 3, 2016 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Amanda Ravitz Geoff Kruczek Caleb French Kate Tillan Tara Harkins Re: Obalon Therapeutics, Inc. Registration Statement on Form S-1 (File No. 333-213551) filed September 9, 2016, as amended Requested Date: October 5, 2016 Requested Time: 4:00 PM Eastern Time Ladies and Gentlemen: Obalon Therapeutics, Inc. (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to declare the above-captioned Registration Statement on Form S-1 effective at the “Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable, or at such later time as the Registrant may orally request via telephone call to the staff of the Commission (the “Staff”). The Registrant hereby authorizes Robert Freedman or Amanda Rose, both of whom are attorneys with the Registrant’s outside legal counsel, Fenwick & West LLP, to orally modify or withdraw this request for acceleration. The Registrant hereby acknowledges that: • should the Commission or the Staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing; • the action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and • the Registrant may not assert the Staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. The Registrant requests that it be notified of such effectiveness by a telephone call to Mr. Freedman at (650) 335-7292 or in his absence, Ms. Rose at (206) 389-4553. Sincerely, OBALON THERAPEUTICS, INC. By: /s/ William Plovanic William Plovanic Chief Financial Officer cc: Andrew Rasdal, Chief Executive Officer Obalon Therapeutics, Inc. Robert Freedman, Esq. Amanda Rose, Esq. Fenwick & West LLP